Premium
Design, Synthesis, Molecular Docking, and Cholinesterase Inhibitory Potential of Phthalimide‐Dithiocarbamate Hybrids as New Agents for Treatment of Alzheimer's Disease
Author(s) -
Asadi Mehdi,
Ebrahimi Mostafa,
MohammadiKhanaposhtani Maryam,
Azizian Homa,
Sepehri Saghi,
Nadri Hamid,
Biglar Mahmood,
Amanlou Massoud,
Larijani Bagher,
Mirzazadeh Roghieh,
Edraki Najmeh,
Mahdavi Mohammad
Publication year - 2019
Publication title -
chemistry and biodiversity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.427
H-Index - 70
eISSN - 1612-1880
pISSN - 1612-1872
DOI - 10.1002/cbdv.201900370
Subject(s) - butyrylcholinesterase , phthalimide , acetylcholinesterase , chemistry , cholinesterase , dithiocarbamate , aché , in vitro , docking (animal) , enzyme , stereochemistry , biochemistry , pharmacology , organic chemistry , biology , medicine , nursing
A novel series of phthalimide‐dithiocarbamate hybrids was synthesized and evaluated for in vitro inhibitory potentials against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The anti‐cholinesterase results indicated that among the synthesized compounds, the compounds 7g and 7h showed the most potent anti‐AChE and anti‐BuChE activities, respectively. Molecular docking and dynamic studies of the compounds 7g and 7h , respectively, in the active site of AChE and BuChE revealed that these compounds as well interacted with studied cholinesterases. These compounds also possessed drug‐like properties and were able to cross the BBB.